Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.

Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Teresa Milner, Joshua Epstein, John Shaughnessy, John Crowley

Blood (2005) 106 (11): 1152.

https://doi.org/10.1182/blood.V106.11.1152.1152

Published: 2005

Journal Articles

Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs “Discontinuous” Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).

Bart Barlogie, Erik Rasmussen, Guido Tricot, Teresa Milner, Elias Anaissie, Frits van Rhee, John Shaughnessy, Joshua Epstein, Klaus Hollmig, Maurizio Zangari, John Crowley

Blood (2005) 106 (11): 1153.

https://doi.org/10.1182/blood.V106.11.1153.1153

Published: 2005

Journal Articles

Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse.

Bart Barlogie, Ichiro Hanamura, Bart Burington, Erik Rasmussen, Peter Stewart, Guido Tricot, Elias Anaissie, Maurizio Zangari, Frits van Rhee, Klaus Hollmig, Teresa Milner, Joshua Epstein, John Crowley, John Shaughnessy

Blood (2005) 106 (11): 1155.

https://doi.org/10.1182/blood.V106.11.1155.1155

Published: 2005

Journal Articles

The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Elias Anaissie, MD, Teresa Milner, BS, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 1157.

https://doi.org/10.1182/blood.V106.11.1157.1157

Published: 2005

Journal Articles

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

John Shaughnessy, PhD, Frank Zhan, PhD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Lisa Jackson, Athanasios Fassas, MD, Maurizio Zangari, MD, Choon-Kee Lee, MD, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 4935.

https://doi.org/10.1182/blood.V104.11.4935.4935

Published: 2004

Journal Articles

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Maurizio Zangari, MD, Julie Stover, Lisa Jackson, Teresa Milner, Athanasios Fassas, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 538.

https://doi.org/10.1182/blood.V104.11.538.538

Published: 2004

Journal Articles

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Athanasios Fassas, MD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Julian Terry, Maurizio Zangari, MD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 932.

https://doi.org/10.1182/blood.V104.11.932.932

Published: 2004

Journal Articles

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Maurizio Zangari, MD, Athanasios Fassas, MD, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, MD, PhD, Choon-Kee Lee, MD, Klaus Hollmig, MD, Giampaolo Talamo, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 934.

https://doi.org/10.1182/blood.V104.11.934.934

Published: 2004

Journal Articles

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Guido Tricot, MD, PhD, John Crowley, PhD, Julie Stover, BA, Teresa Milner, BS, Athanasios Fassas, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Elias Anaissie, MD, Frits van Rhee, MD, PhD, Giampalamo Talamo, MD, Klaus Hollmig, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 936.

https://doi.org/10.1182/blood.V104.11.936.936

Published: 2004

NARROW

Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.

Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs “Discontinuous” Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).

Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse.

The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only